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Stem cell tourism describes the Internet-based industry where in patients receive unproven stem cell
interventions. To better inform the public, several organizations provide educational material on stem cell
therapies and tourism; however, an assessment of the currently available resources reveals a lack of compre-
hensive information, suggesting that further efforts are needed.‘‘Stem cell tourism’’ refers to the online,
direct-to-consumer advertised industry
wherein patients travel to receive un-
proven stem-cell-based interventions.
Although it is nearly impossible to accu-
rately calculate the number of patients
who have received an unproven stem
cell intervention, many suspect this
number to be in the tens of thousands
or more. And despite frequent criticism
from the scientific community, regulators,
and professional organizations, the indus-
try continues to flourish. Providers adver-
tise to patients by underplaying risks,
peddling hope, and attempting to stifle
warnings. In addition to the problem of
financial exploitation, the provision of un-
proven interventions has been associated
with causing tremors, tumors, lesions,
and death. The term ‘‘stem cell tourism’’
itself is misleading because it focuses on
patient behavior and does not reflect the
reality that patients do not always need
to travel. In total, stem cell tourism re-
mains a significant policy challenge.
Some debates about curbing unap-
proved stem cell interventions center
on tightening regulations. And several
policy and enforcement initiatives have
had limited success, as evidenced by
the closure of clinics, sanctioning of
physicians, and prosecution of scientists
for manufacturing and distributing unap-
proved interventions (Master et al., 2013;
Zarzeczny et al., 2014). Another major
policy approach has been to improve the
information available to patients, thus
ensuring that patients are well informed
prior to deciding whether to undergo
an unproven stem cell intervention (Zar-zeczny and Caulfield, 2010; Levine and
Wolf, 2012). Several organizations have
invested significantly in public/patient
education by developing handbooks
on stem cell therapies and unproven inter-
ventions, including the International Soci-
ety for Stem Cell Research’s (ISSCR’s)
A Closer Look website (http://www.
closerlookatstemcells.org). But to date,
there has been no systematic assessment
of the accessibility or comprehensiveness
of publically available educational con-
tent—an examination necessary in order
to begin to determine the effective-
ness of public education on stem cell
pseudomedicine.
Here, we discuss the content of web-
based, educational material on unproven
stem cell interventions and clinical trans-
lation. Because stem cell pseudomedi-
cine is an Internet-based industry, it
seems that patients and caregivers are
likely to use the Internet to find information
about stem cell treatments. Moreover,
research tells us that the public increas-
ingly turns to the Internet for information
about science and health (Pew Research
Center’s Internet & American Life Project,
2011). In addition to information about
stem cell treatments, patients may also
seek general information about stem cell
biology, clinical translation of stem cells,
and ethical and policy issues. Patients
may also turn to local, regional, state,
national, or international patient advocacy
groups related to their condition to seek
information, especially when bombarded
with positively enforced advertisements
for stem cell therapies in the media
(Zarzeczny et al., 2010). Therefore, inCell Stem Cell 15, Sorder to assess the nature and quality
of available Internet-based material, we
evaluated the educational content of 175
scientific organizations and patient advo-
cacy groups on stem cell science, ethics,
and policy and the clinical translation of
stem cells and unproven interventions.
We expected that, while there is some
educational information on stem cell sci-
ence and regenerative medicine, there
would be little information on unproven
stem cell interventions.
Organizations and Their Scope
Through keyword searches using http://
www.google.ca, we identified 25 scienti-
fic societies, 10 stem cell research
networks, 15 funders, and 125 patient
advocacy groups.We based the selection
of advocacy groups on the top five dis-
eases that motivated individuals to travel
to receive stem cell interventions: multiple
sclerosis (MS), cerebral palsy (CP), spinal
cord injury (SCI), amyotrophic lateral scle-
rosis (ALS), and Parkinson’s disease (PD)
(25 each) (Zarzeczny et al., 2010; Rachul,
2011). Efforts were concentrated on
patient advocacy groups because they
are known to provide educational infor-
mation on the latest clinical developments
and patients seem likely to be aware of
and visit the websites of such groups.
We assured that each organization fit
the description of a scientific society,
research network, funder, or patient
advocacy group. See our Supplemental
Information for further details on how we
evaluated the organizations.
Jurisdictional coverage of the scienti-
fic and patient advocacy groups waseptember 4, 2014 ª2014 Elsevier Inc. 267





Networks (%) Funders (%)
Patient Advocacy
Groups (%)
Science 43 67 49 21
Ethics/Policy 27 53 22 13
Treatment/Unproven
Stem Cell Interventions
9 39 12 12
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tional (11%) scope. Most organizations
had national (38%) or state/provincial
(30%) coverage. Most scientific societies
(56%) had an international scope and
the majority of research networks (67%)
and funders (53%) had national reach.
Patient advocacy groups tended to
have equal national or state/provincial
coverage (36% and 37%, respectively).
Overall, the organizations we identified
represented a total of 33 different coun-
tries, most of which were US-based
(44%), followed by those in by Canada
(24%), Australia (9%), and the UK (7%).
Educational Content on Stem Cell
Science, Ethics, and Policy
We examined websites for educational
content on three topics: (1) stem cell sci-
ence; (2) stem cell ethics and policy; and
(3) stem cell treatments, clinical transla-
tion, and pseudomedicine.
Overall, scientific organizations had
significantly more content about stem
cell science than patient advocacy groups
(c2 = 32.6; df = 5, N = 175, p < 0.001)
(Table 1). In addition, scientific organiza-
tions had more content on ethical and
policy issues related to embryo and
stem cell research, or human subjects
research, than patient advocacy groups
(c2 = 33.3, df = 6, N = 175, p < 0.001).
Specifically, we observed that research
networks had more information com-
pared to scientific societies and funders
on stem cell science (c2 = 16.8, df = 10,
N = 50, p = 0.079) and on ethics and policy
(c2 = 18.2, df = 12, N = 50, p = 0.109)
(Table 1). We also found that ALS patient
advocacy groups had slightly more
coverage than other advocacy groups
and CP patient advocacy groups had
the least content on science and ethics/
policy, although differences were not
statistically significant.
Given that most scientific organiza-
tions have a mandate to educate scien-268 Cell Stem Cell 15, September 4, 2014 ª2tists and the public on stem cell
research, it was not surprising that 72%
of scientific organizations had at least
some web-based content. Similarly, it
seemed appropriate that many scientific
organizations posted information on one
or more ethics-related topics (e.g., the
moral status of human embryos) and
outlined policy issues related to stem
cell research because these discussions
were the main focus of early policy
debates. It is only relatively recently that
there has been emphasis on policy
issues associated with the translation
of stem cell research (Caulfield et al.,
2012). Still, less than half of the patient
advocacy groups had any web-based
educational content, and while their
mandates may capture educating pa-
tients about the disease, they would not
necessarily capture advances in stem
cell research or the associated ethical/
policy issues.
The Missing Elements: Stem Cell
Clinical Translation and Unproven
Interventions
In a previous study, we examined the
content and outlined several elements
to consider when developing educational
material for patients and the public on
stem cell treatments and pseudomedi-
cine (Master et al., 2013):
d illustrating differences between es-
tablished stem cell therapies, legiti-
mate clinical research, and pseudo-
medicine;
d describing hallmarks of clinics offer-
ing unproven interventions (e.g., us-
ing one type of stem cell to treat
many diseases);
d explaining risks associated with
unproven stem cell interventions;
d explaining different kinds of evi-
dence and why some, i.e., patient
testimonials, should not be given
much weight; and014 Elsevier Inc.d providing a description of the clin-
ical translation process and the
need for proper ethics and regula-
tory oversight to ensure safety and
efficacy.
The last point is especially important
to discuss because studies indicate that
patients may not fully understand the
regulatory pathway and may distrust their
domestic research and regulatory estab-
lishments, considering them unrespon-
sive to their needs (Rachul, 2011). The
expectation that treatments are available
in other countries could be spurred by
media hype of medical breakthroughs
in stem cell research and reinforced by
advertisements from clinics and endorse-
ments from people who have visited
them. For these reasons, patient informa-
tion should describe the clinical transla-
tion process in order to help address
questions of why it might take so long to
develop stem cell therapies (Master
et al., 2013).
While organizations had some content
on the science of stem cells, we were
somewhat surprised to find that, overall,
both scientific organizations (16%) and
patient advocacy groups (12%) had
equally little information on stem cell
treatments, the clinical translation pro-
cess, and stem cell pseudomedicine
(c2 = 0.000, df = 1, N = 175, p = 0.566).
Almost a quarter of scientific organiza-
tions and even fewer patient advocacy
groups defined the concept of stem cell
pseudomedicine, and only a handful of
both sets of organizations had educa-
tional material explaining the clinical
translation process and the need for
ethics and regulatory approval (Figure 1);
of these, many discussed clinical trans-
lation outside the context of stem cell
research, which was not differentiated
during coding.
These results show that while scientific
organizations had some content on stem
cell science and less on ethics and policy,
overall, both scientific organizations and
patient advocacy groups had very little
information on stem cell treatments and
pseudomedicine.
A Realistic Outlook on Patient
Education
Educating patients and caregivers, while
valuable in its own right, seems unlikely
to significantly alter the demand for
Figure 1. Percent Education Content on Stem Cell Tourism and Clinical Translation
From left to right, the Stem Cell Science category includes educational content on stem cell biology
(SC Biol) and regenerative medicine (Reg Med). The Unproven Stem Cell Interventions & Clinical Transla-
tion category includes educational content: defining ‘‘stem cell tourism’’ (Defn SCTourism), explaining that
there is little or no evidence to offer many stem cell interventions (No Evidence), outlining the risks of
unproven stem cell interventions (Risks), explaining that there are very few established stem cell therapies
(Established Therapies), stating that patient testimonials are not the only means of demonstrating treat-
ment efficacy (Testimonials), explaining what patients should look for when considering a stem cell inter-
vention (Patients Look For), explaining the clinical translation process (Clinical Translation), explaining the
need for regulatory and ethics oversight (Regulations & Ethics), and explaining the concept of medical
innovation (Medical Innovation). Please see the codebook in Supplemental Information for further details
of each subcategory.
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dence and expert advice are only one of
many factors that influence decisions
about these services. As noted by Alan
Petersen, the educational ‘‘approach is
underpinned by a rational actor model
that assumes that individuals will ratio-
nally weigh up options in light of available
information before deciding on the
optimal decision. It overlooks the context
in which identity is formed and hope as-
sumes meaning’’ (Petersen et al., 2013).
Still, educating patients will help them
make more informed healthcare deci-
sions irrespective of whether education
is effective at dissuading patients from
seeking unproven interventions (Master
et al., 2013).
It is important to recognize what exist-
ing evidence tells us about the potentially
limited impact of education. For example,
a recent study found that educating par-
ents with antivaccination attitudes did
little to alter their vaccination behavior
(Nyhan et al., 2014). While evidence-
based health information refuting the
vaccine/autism link regarding measles-
mumps-rubella (MMR) vaccination made
parents more informed, it failed to alter
their decision to vaccinate their children.Information in the form of images of chil-
drenwithMMRor a narrative about a child
who had measles resulted in reinforcing
beliefs in the serious side-effects of
vaccines. Although the question about
whether education changes the minds of
patients to seek unproven stem cell inter-
ventions remains empirically unassessed,
the above study suggests that patient
information may be helpful at correcting
some misinformation (e.g., debunking
providers’ claims that stem cell interven-
tions are risk free), but it may not dissuade
patients from seeking unproven interven-
tions. While today the unproven market
of stem cell interventions for most dis-
eases can be clearly distinguished, this
separation is likely to become increas-
ingly obscure as more stem cell research
enters clinical phases. As a result, the
blurring between unapproved but legiti-
mate clinical research andmore question-
able unproven interventions will make it
difficult for patients to navigate the clinical
stem cell landscape. Thus, one of the
goals of education on stem cell therapies
is to help clarify concepts, explain how
research leads to products, and help
patients discern between legitimate
research and fraudulent therapies. Arm-Cell Stem Cell 15, Sing patients with the right information is
valuable irrespective of the decisions
they make on whether to undergo an
unproven stem cell intervention.
While a few organizations, such as the
ISSCR, the National StemCell Foundation
of Australia and Stem Cells Australia
(http://www.stemcellfoundation.net.au/
patient-information/handbook), Canada’s
Stem Cell Network, the California Institute
for Regenerative Medicine, and the UK
MSSociety (http://www.mssociety.org.uk/
ms-resources/stem-cell-therapies-and-
ms-booklet), have made significant ef-
forts to develop education to help explain
stem cell therapies to people seeking
treatment, our data clearly shows an over-
all lack of web-based information. There
appears to be a gap in basic information
about stem cell research and therapy,
the translation process, and stem cell
pseudomedicine. Greater efforts are
needed to develop educational materials,
especially by patient advocacy groups
because they are a trusted source of
information for patients. While we have
previously commented on the content of
patient booklets (Master et al., 2013),
these booklets need to also address
limitations of the current system (e.g.,
the present need for more efficient regu-
latory pathways to handle stem cell
interventions) and should avoid using
preachy language or a finger-wagging
tone. In addition, the booklet should be
made simple and easy to read while
maintaining scientific accuracy. Delivery
of the message should adopt a neutral
tone that is meant to provide unbiased
information—attributes we recently at-
tempted by developing a patient booklet
based on our work (http://www.amc.
edu/stemcellbooklet).
Many patients strive to gain an under-
standing of stem cell research and how
it might be able to help them through
self-directed learning, asking questions
of their physicians (Levine and Wolf,
2012), and contacting patient advocacy
groups. While our results indicate the
need to develop more educational mate-
rials, uptake of the information requires
effective delivery. In addition to physi-
cians offering educational information to
patients, patient advocacy groups can
make a significant impact in delivering in-
formation to their constituency. Because
many patient advocacy groups are volun-
teer run, they cannot be expected toeptember 4, 2014 ª2014 Elsevier Inc. 269
Cell Stem Cell
Forumdevelop their own educational booklet
on stem cell therapies. However, they
can collaborate and help disseminate
materials created by scientific and other
professional organizations. Patient advo-
cacy groups have an additional advan-
tage over other professional organiza-
tions in that they are highly trusted by
patients. Several criticisms have been
made that scientists and other experts
have ‘‘conflicts of interest’’ in that these
professionals are biased toward their
own agendas and do not sufficiently
consider the needs of patients (Knoepfler,
2012). While these accusations may not
rest on solid ground, they could deter
the effective delivery of information to
patients. As such, increased efforts are
needed to not only develop educational
material, but to also communicate with
patient advocacy groups so they can
provide a coordinated response, reaffirm
the need for effective scientific research
and regulatory oversight, and promote
educational information on stem cell ther-
apies to patients (Master and Sipp, 2013).
We need to be realistic in our expecta-
tions of education as a means to deter
patients from seeking unproven interven-
tions. Providing education is important
if only to inform patients about stem cell
therapies in order to help them better
navigate the clinical landscape. Because
there are a few reports of patients who
are skeptical of provider practices (Ra-
chul, 2011) or regret their decisions to
undertake unproven stem cell interven-
tions (Miles, 2008), it remains conceivable
that education might help some recon-270 Cell Stem Cell 15, September 4, 2014 ª2sider options. It is important for the
scientific, medical, ethics, and policy
communities to continue to promote
accurate patient and public information
on stem cell research and tourism and to
ensure that it is effectively disseminated
to patients by working alongside patient
advocacy groups. Coordinated efforts
by governments, scientific organizations,
the medical and ethics communities,
and patient advocacy groups are needed
if we are to realistically and significantly
stifle the stem cell pseudomedicine
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